FFO
NRIX icon

Fortitude Family Office’s Nurix Therapeutics NRIX Stock Holding History

Fortitude Family Office’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$735 Hold
31
– – ﹤0.01% 2319
2026
Q2 		$752 Hold
31
– – ﹤0.01% 1858
2026
Q1 		$481 Buy
+31
New +$514 ﹤0.01% 1745

Other funds holding NRIX

WFA
WestHill Financial Advisors San Rafael, California $597M AUM 13.09% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Fortitude Family Office's NRIX Position: Q3 2026 in Review

Fortitude Family Office held its Nurix Therapeutics (NRIX) position steady in Q3 2026 at 31 shares worth $735. The position accounts for ﹤0.01% of the portfolio, ranked #2319.

Fortitude Family Office first reported a position in NRIX in Q1 2026 and has held it in 3 quarters since. The position peaked at $752 in Q2 2026. 8 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Fortitude Family Office held 31 shares of Nurix Therapeutics worth $735 as of Q3 2026.
  • Fortitude Family Office left its Nurix Therapeutics share count unchanged in Q3 2026.
  • Nurix Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #2319 holding.
  • Fortitude Family Office first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Fortitude Family Office's Nurix Therapeutics position peaked at $752 in Q2 2026.
  • 8 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.